Research programme: nanomedicines - BIND Therapeutics/Merck & CoAlternative Names: KSP Accurin™ - BIND Therapeutics/Merck & Co; KSP inhibitors - BIND Therapeutics/Merck & Co; PLK1 Accurin™ - BIND Therapeutics/Merck & Co; PLK1 inhibitors - BIND Therapeutics/Merck & Co
Latest Information Update: 15 Jul 2016
At a glance
- Originator BIND Therapeutics; Merck & Co
- Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Proto oncogene protein c-akt inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer